Ziopharm Oncology Inc. (Nasdaq: ZIOP) received positive guidance from the Food and Drug Administration at its End-of-Phase 2 meeting for Ad-RTS-hIL-12 gene therapy candidate. The stock price gained 81 cents to close at $6.69.
FDA provides positive guidance to Ziopharm Oncology
March 27, 2017 at 18:57 PM EDT